表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）的问世开启了 EGFR 突变非小细胞肺癌（NSCLC）的精准治疗时代，特别是三代 EGFR-TKI 奥希替尼，凭借着显著的全身和颅内疗效获益，已成为此类患者的一线标准治疗方案[1-3]。然而，EGFR-TKI 单药治疗存在一定的局限性，比如存在 EGFR L858R ...

表皮生长因子受体（EGFR）突变非小细胞肺癌（NSCLC）具有高度异质性，EGFR 突变类型、共突变状态、肿瘤负荷等均可能影响其靶向治疗效果。FLAURA2 研究最终总生存期（OS）数据显示，一线奥希替尼联合化疗可显著延长 EGFR 突变晚期 ...

Identification of a specific genetic mutation in patients with non-small-cell lung cancer (NSCLC) helps clinicians select the best treatment option. Potential NSCLC patients usually undergo invasive ...

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...

Stage III NSCLC: What Are the Treatment Options Today?

16.0 months median progression-free survival (mPFS) with firmonertinib indicates strong efficacy in first-line patients with EGFR PACC mutant non-small cell lung cancer (NSCLC). Robust central nervous ...

SAN DIEGO--(BUSINESS WIRE)--Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced findings from a study using the Cellworks Platform ...

Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R ...

For patients with non–small cell lung cancer (NSCLC) that has tested positive for EGFR mutations, treatment with targeted EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib (Tarceva, Osi ...

The genetic mutations underlying treatment resistance in non-small cell lung cancer (NSCLC) are more complex and dynamic than previously thought. Analysis of 355 biopsied tumors from patients who ...